bullish

Lotus Pharmaceutical (1795 TT): Record-High Performance in 2023; What Lies Ahead?

275 Views21 Mar 2024 09:30
SUMMARY
  • Lotus Pharmaceutical (1795 TT) achieved 16% revenue growth to NT$17B in 2023, while net profit increased 36% to NT$4B. Growth was mainly driven by the strong performance of Asian business.
  • For the first two months of 2024, the company reported revenue of NT$3B, representing 1% YoY decline. While exports grew, Asia business remained flat.
  • 1Q24 should be flat or slightly negative for the company, while growth is expected to pick up from the later half of the year.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
chart-bar
x